<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183895</url>
  </required_header>
  <id_info>
    <org_study_id>4631</org_study_id>
    <nct_id>NCT03183895</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study</brief_title>
  <official_title>Safety and Performance Evaluation of the AccuCinch® Ventricular Repair System for the Treatment of Heart Failure With or Without Functional Mitral Regurgitation Due to Dilated Ischemic or Non-Ischemic Cardiomyopathy - The CorCinch-EU Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ancora Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ancora Heart, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective, non-randomized, single-arm, international, multicenter, clinical safety
      and performance clinical investigation to evaluate the AccuCinch® Ventricular Repair System
      for the treatment of heart failure, with or without functional mitral regurgitation due to
      dilated ischemic or non-ischemic cardiomyopathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study are to evaluate the safety and performance of the
      AccuCinch Ventricular Repair System for the treatment of heart failure and functional mitral
      regurgitation in symptomatic adult patients with or without functional mitral regurgitation
      (FMR) and left ventricular remodeling due to dilated cardiomyopathy (ischemic or non-ischemic
      etiology), who remain symptomatic despite optimized medical therapy.

      Subjects with FMR must present with at least moderate FMR, a reduced ejection fraction (≤40%)
      and high operative risk as assessed by the Heart Team. The Heart Team may utilize established
      risk scores (STS, Euro-Score II) in conjunction with comorbidities as recommended by MVARC
      (frailty index; major organ system compromise not to be improved postoperatively; procedure
      specific impediments).

      Subjects without FMR must present a markedly dilated left ventricle with LVEDD ≥ 55 mm and
      reduced ejection fraction (≤40%). These patients are not potential candidates for
      &quot;conventional intervention&quot;, because their mitral valve is not in need of repair or
      replacement. Therefore, AccuCinch represents the sole treatment option for these patients,
      who are not selected on the basis of high surgical risk.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety outcome: 30-day major adverse events (MAEs)</measure>
    <time_frame>30-day</time_frame>
    <description>Major adverse event (MAE) where MAE is a composite of the following device- or procedure-related events:
A. All-cause mortality
B. Stroke
C. Life-threatening bleeding (MVARC scale)
D. Major vascular complications
E. Major cardiac structural complications
F. Myocardial infarction or coronary ischemia requiring PCI or CABG
G. Stage 2 or 3 acute kidney injury (includes new dialysis)
H. Severe hypotension, worsening of heart failure, or respiratory failure requiring intravenous pressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for &gt;48 h.
I. Emergency surgery or re-intervention related to the device or access procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success: Successful access, delivery, and retrieval of AccuCinch System components, successful deployment of the AccuCinch implant without need for unplanned or emergency surgery or re-intervention</measure>
    <time_frame>30-day</time_frame>
    <description>Successful access, delivery, and retrieval of all AccuCinch catheters. Deployment and correct positioning of the intended AccuCinch implant, and no need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure measured upon completion of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural performance: Assessment of device integrity</measure>
    <time_frame>30-day</time_frame>
    <description>No migration, embolization, detachment, fracture, hemolysis, thrombosis or endocarditis; and no para-device complications (erosion, effusion requiring surgery or drainage or producing tamponade, damage to the MV apparatus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Freedom from re-hospitalizations or re-interventions for the underlying condition</measure>
    <time_frame>30-day</time_frame>
    <description>Freedom from re-hospitalizations or re-interventions for the underlying condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Improvement in NYHA functional class</measure>
    <time_frame>30-day</time_frame>
    <description>Improvement in NYHA functional class when compared to baseline assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Improvement in six-minute walk test</measure>
    <time_frame>30-day</time_frame>
    <description>Improvement in six-minute walk test (6MWT) when compared to baseline assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life (QoL)</measure>
    <time_frame>30-day</time_frame>
    <description>Improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life (QoL) when compared to baseline</description>
  </secondary_outcome>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathies</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral valve repair</intervention_name>
    <description>The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Subjects who present with heart failure with or without functional mitral
             regurgitation due to dilated cardiomyopathy of ischemic or non-ischemic etiology

               1. For subjects with FMR, severity of FMR: ≥ Moderate 2+

               2. For subjects without FMR, LVEDD ≥ 55 mm

          -  Ejection Fraction: ≥20 to ≤40%

          -  Symptom Status: NYHA II-IVa

          -  Patients to be considered for the present study will be required to have received all
             appropriate guidelines-recommended therapies for at least 3 months prior to the
             enrollment with stable doses of drugs for at least 1 month.

          -  Surgical risk:

               1. For patients with FMR only: the Heart Team must assess as high-risk and may
                  utilize risk score or comorbidities to demonstrate high risk features. High risk
                  for mitral valve surgery is defined utilizing established risk scores (STS,
                  Euro-Score II) in conjunction with comorbidities as recommended by MVARC (frailty
                  index; major organ system compromise not to be improved postoperatively;
                  procedure specific impediments) (MVARC Part 1)

               2. For all patients: Subject is eligible for cardiac surgery (namely, the patient is
                  in a condition that allows a potential conversion to open surgery in case of
                  procedural complications). This criterion adds a safety level for the patients

          -  Completion of all qualifying diagnostic and functional tests and agrees to comply with
             study follow-up schedule

          -  Patients required to have an ICD are required to have ICD implant at least 1 month
             prior to enrollment

        Exclusion Criteria:

          -  Life expectancy &lt;1 yr due to noncardiac conditions

          -  NYHA functional class IVb or ACC/AHA stage D heart failure

          -  Hypotension (systolic pressure &lt;90 mm Hg) or requirement for inotropic support or
             mechanical hemodynamic support

          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or
             any other structural heart disease causing heart failure other than dilated
             cardiomyopathy of either ischemic or nonischemic etiology

          -  Fixed pulmonary artery systolic pressure &gt;70 mm Hg

          -  Physical evidence of right-sided congestive heart failure with echocardiographic
             evidence of moderate or severe right ventricular dysfunction

          -  Mitral valve anatomy which may preclude proper device treatment

          -  Mitral valve area &lt;4.0 cm2 (if new device therapy may further decrease the mitral
             orifice area)

          -  Any prior mitral valve surgery or transcatheter mitral valve procedure

          -  Stroke or transient ischemic event within 30 days

          -  Modified Rankin Scale ≥ 4 disability

          -  Need for emergent or urgent surgery for any reason or any planned cardiac surgery
             within the next 12 months

          -  Untreated clinically significant coronary artery disease requiring revascularization

          -  Severe symptomatic carotid stenosis (&gt;70% by ultrasound).

          -  Myocardial infarction ≤ 30 days

          -  Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid
             surgery within 30 days

          -  Tricuspid valve disease requiring surgery or severe tricuspid regurgitation (per ASE
             guidelines; core lab assessment)

          -  Aortic valve disease requiring surgery

          -  Moderate or severe aortic valve stenosis or regurgitation

          -  Aortic valve prosthesis

          -  Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile
             aortic atheroma, intracardiac mass, thrombus, or vegetation

          -  Need for any cardiovascular surgery (other than for MV disease)

          -  Active endocarditis

          -  Anatomical pathology/constraints preventing appropriate access/implant of the
             AccuCinch System (e.g., femoral arteries will not support an 20F system)

          -  Known allergy to nickel, polyester, or polyethylene

          -  Active infections requiring current antibiotic therapy

          -  Subjects in whom transesophageal echocardiography is contraindicated

          -  Renal insufficiency (i.e., eGFR of &lt;30ml/min/1.73m2; Stage 4 or 5 CKD)

          -  Subjects in whom anticoagulation or antiplatelet therapy is contraindicated

          -  Any prior true anaphylactic reaction to contrast agents; defined as known
             anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that
             cannot be adequately pre-medicated prior to procedure.

          -  Implant or revision of any rhythm management device (CRT or CRT-D) or implantable
             cardioverter defibrillator within 1 month

          -  Absence of CRT with class I indication criteria for biventricular pacing (left bundle
             branch block pattern and QRS duration ≥150 ms)

          -  Subjects on high dose steroids or immunosuppressant therapy

          -  Any condition making it unlikely the patient will be able to complete all protocol
             procedures (including compliance with guideline directed medical therapy) and
             follow-up visits

          -  Patient (or legal guardian) unable or unwilling to provide written, informed consent
             before study enrollment. This study excludes vulnerable populations as defined in
             protocol section 18.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <role>Study Director</role>
    <affiliation>Ancora Heart, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <phone>408-727-1105</phone>
    <phone_ext>204</phone_ext>
    <email>mzapien@ancoraheart.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey Strader</last_name>
    <phone>+33771570784</phone>
    <email>astrader@ancoraheart.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre of Cardiology</name>
      <address>
        <city>Minsk</city>
        <zip>220036</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alena Kurlianskaya, MD, PhD</last_name>
      <email>akurlianskaya@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alena Kurlianskaya, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oleg Polonetsky, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwziekenhuis</name>
      <address>
        <city>Aalst</city>
        <state>Aaslt</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozef Bartunek, Dr</last_name>
      <email>jozef.bartunek@telenet.be</email>
    </contact>
    <contact_backup>
      <last_name>Kathy De Kniff</last_name>
      <email>Kathy.De.Knijf@olvz-aalst.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jozef Bartunek, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>10800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Van der Heyden, Dr</last_name>
      <email>Jan.VanDerHeyden@azsintjan.be</email>
    </contact>
    <contact_backup>
      <last_name>Datrien Derycker</last_name>
      <email>Katrien.Derycker@azsintjan.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jan Van der Heyden, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Coling</last_name>
    </contact>
    <contact_backup>
      <last_name>Petr Moucka</last_name>
      <email>Petr.Moucka@homolka.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Petr Neuzil</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivek Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pessac (CHU Bordeaux)</name>
      <address>
        <city>Pessac</city>
        <state>Avenue Magellen</state>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Leroux, Dr</last_name>
      <email>lionel.leroux@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christel Duprat</last_name>
      <email>cic.cardio@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Louis Labrousse, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane Lafitte, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Gilard, Pr</last_name>
      <email>martine.gilard@chu-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Tiphaine Menez</last_name>
      <email>tiphaine.menez@chu-brest.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Martine Gilard, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardio-Vasculaire Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François Obadia, Pr</last_name>
      <email>jean-francois.obadia@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Carine Flys</last_name>
      <email>carine.flys@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-François Obadia, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Riougol, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Williams Hulrich, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sohpie Thivolet, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Coeur-Poumon</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Modine, Dr</last_name>
      <email>thomas.modine@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Meriem Hellal</last_name>
      <email>meriem.hellal@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Modine, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Sudre, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Augustin Coisne, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>André Vincentelli, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Cuisset, Dr</last_name>
      <email>thomas.cuisset@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aurélie Blondelon</last_name>
      <email>aurelie.blondelon@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Cuisset, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Deharo, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gibert Habib, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Jacques Cartier - Massy</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lefèvre, Dr</last_name>
      <email>t.lefevre@icps.com.fr</email>
    </contact>
    <contact_backup>
      <last_name>Séverine Roger</last_name>
      <email>s.roger@icps.com.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thierry Lefèvre, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Chevalier, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Hovasse, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand Cormier, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris Hôpital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe Collet, Pr</last_name>
      <email>jean-philippe.collet@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Delphine Brugier</last_name>
      <email>delphine.brugier@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Philippe Collet, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Barthelemy, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Isnard, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Le Prince, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lise Le Grand, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Claude-Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Himbert, Dr</last_name>
      <email>dominique.himbert@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Reza Farnoud, Phd</last_name>
      <email>Reza.farnoud.bch@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Grégory Ducrocq, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Urena-Alcazar, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Brochet, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Leurent, Dr</last_name>
      <email>Guillaume.LEURENT@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuelle Babin-Lerede</last_name>
      <email>Emmanuelle.BABIN-LEREDE@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Hervé Le Breton, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Leurent, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Galli, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Ohlmann, Pr</last_name>
      <email>patrick.ohlmann@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Dessilava Ivanona</last_name>
      <email>dessislava.ivanova@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Ohlmann, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Morel, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Floriane Zeyons, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annie Trinh, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Dumonteil</last_name>
      <email>ndumonteil@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Nicolas Dumonteil, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Tchetche, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>Milano</city>
        <state>Piazza Edmondo Malan, 1 San Donato Milanese,</state>
        <zip>20037</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federico De Marco, Pr</last_name>
      <email>federico.demarco@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Federico De Marco, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Dedogni, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <state>Via Madonna Di Genova, 1,</state>
        <zip>48033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Colombo, Pr</last_name>
      <email>colombo@emocolumbus.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Colombo, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Mangieri, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Ferrari, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Via Olgettina, 60,</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Paolo, Dr</last_name>
      <email>denti.paolo@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Paolo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrius Aidietis, Pr</last_name>
      <email>Audrius.aidietis@santa.lt</email>
    </contact>
    <contact_backup>
      <last_name>Odeta Pazeriene</last_name>
      <email>o.pazeriene@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Audrius Aidietis, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gitana Zuozienė, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vytė Maneikienė, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mindaugas Matačiūnas, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kęstutis Ručinskas, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valdas Bilkis, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giedrius Davidavičius, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Zakarkaitė, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Kramena, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gintarė Gintarė Bieliauskien, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Bosschaert</last_name>
      <email>m.bosschaert@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>B.J.W.M. Rensing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas van Mieghem</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas van Mieghem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zenon Huczek, Pr</last_name>
      <email>zenon.huczek@wum.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Bartosz Rymuza, Dr</last_name>
      <email>bartosz.rymuza@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zenon Huczek, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Rdzanek, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bartosz Rymuza, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Scislo, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janusz Kochman, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Trust</name>
      <address>
        <city>London</city>
        <state>Sydney St, Chelsea, London</state>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ShuFang Wang</last_name>
      <email>s.wang@rbht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Teijo Palovaara</last_name>
      <email>T.Palovaara@rbht.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Rob Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital, Belfast Trust</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Spence</last_name>
      <email>marks.spence@belfasttrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Mark Spence</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

